• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

影响血液透析患者贫血管理的因素:单中心经验

Factors affecting anemia management in hemodialysis patients: a single-center experience.

作者信息

Spiegel David M, Gitlin Matthew, Mayne Tracy

机构信息

University of Colorado Health Sciences Center, Denver, Colorado, USA.

出版信息

Hemodial Int. 2008 Jul;12(3):336-41. doi: 10.1111/j.1542-4758.2008.00278.x.

DOI:10.1111/j.1542-4758.2008.00278.x
PMID:18638090
Abstract

The difficulty maintaining hemoglobin (Hgb) within the targets recommended by KDOQI is widely recognized. While factors responsible for erythropoietin resistance have been widely studied, factors responsible for the marked fluctuations and the inability to maintain Hgb within the target range have only begun to be investigated. This study was a cross-sectional review of anemia management in hemodialysis patients. The purpose was to evaluate factors responsible for Hgb decreases of 0.5 or 1.0 g/dL and to determine the primary factors responsible for Hgb decreases below 11 g/dL. Hgb values and clinical events were extracted from patient management databases between January 1, 2005 and November 30, 2006. Isolated events were defined as events that occurred at least 30 days after any previous event and had Hgb measurements within 2 weeks before and after the event. Increasing hospital length of stay and surgical access intervention were the most common events that resulted in a decrease in Hgb. The most common factor present in patients with Hgb decreases below 11 g/dL was the withholding of recombinant human erythropoietin (rHuEPO) within the preceding 2 months. This was the only explanation for the decrease in Hgb to <11 g/dL in 38.5% of such events. The ability to maintain dialysis patients' Hgb in the target range is complicated by intervening acute events that require hospitalization or surgical access interventions. The withholding of rHuEPO appears to be a major factor in Hgb decreases below 11 g/dL.

摘要

人们普遍认识到,将血红蛋白(Hgb)维持在KDOQI推荐的目标范围内存在困难。虽然对促红细胞生成素抵抗的相关因素已进行了广泛研究,但对于导致Hgb显著波动以及无法将其维持在目标范围内的因素,才刚刚开始研究。本研究是对血液透析患者贫血管理的横断面回顾。目的是评估导致Hgb下降0.5或1.0 g/dL的因素,并确定导致Hgb降至11 g/dL以下的主要因素。从2005年1月1日至2006年11月30日期间的患者管理数据库中提取Hgb值和临床事件。孤立事件定义为在任何先前事件至少30天后发生且在事件前后2周内有Hgb测量值的事件。住院时间延长和手术通路干预是导致Hgb下降的最常见事件。Hgb降至11 g/dL以下的患者中最常见的因素是在之前2个月内停用重组人促红细胞生成素(rHuEPO)。在38.5%的此类事件中,这是Hgb降至<11 g/dL的唯一原因。需要住院治疗或进行手术通路干预的急性事件会干扰维持透析患者Hgb在目标范围内的能力。停用rHuEPO似乎是Hgb降至11 g/dL以下的一个主要因素。

相似文献

1
Factors affecting anemia management in hemodialysis patients: a single-center experience.影响血液透析患者贫血管理的因素:单中心经验
Hemodial Int. 2008 Jul;12(3):336-41. doi: 10.1111/j.1542-4758.2008.00278.x.
2
Effect of variability in anemia management on hemoglobin outcomes in ESRD.终末期肾病患者贫血管理的变异性对血红蛋白结果的影响。
Am J Kidney Dis. 2003 Jan;41(1):111-24. doi: 10.1053/ajkd.2003.50030.
3
Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.口服十全大补汤/TJ - 48可改善血液透析患者对促红细胞生成素(rHuEPO)抵抗性贫血的症状。
Hemodial Int. 2008 Oct;12 Suppl 2:S9-S14. doi: 10.1111/j.1542-4758.2008.00317.x.
4
Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI.慢性肾衰竭贫血管理的当前概念:NKF-DOQI的影响
Semin Nephrol. 2000 Jul;20(4):320-9.
5
Correlates affecting survival in chronic hemodialysis patients: the combined impact of albumin and high hemoglobin levels on improving outcomes, local and national results.影响慢性血液透析患者生存的相关因素:白蛋白和高血红蛋白水平对改善预后的综合影响,本地及全国性结果。
Hemodial Int. 2008 Oct;12(4):450-62. doi: 10.1111/j.1542-4758.2008.00309.x.
6
Prevalence and severity of anemia in pediatric hemodialysis patients.小儿血液透析患者贫血的患病率及严重程度
Saudi Med J. 2007 Feb;28(2):249-53.
7
What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease.在终末期肾病中,要使血红蛋白达到11.0 - 13.0克/分升需要什么。
Blood Purif. 2007;25(1):53-7. doi: 10.1159/000096398. Epub 2006 Dec 14.
8
Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients.血液透析患者的方案依从性及达到目标血红蛋白水平的能力。
Nephrol Dial Transplant. 2009 Jun;24(6):1956-62. doi: 10.1093/ndt/gfn780. Epub 2009 Jan 28.
9
[Study of immutable variables determining rHuEPO dose requirements on hemodialysis patients].
Nefrologia. 2005;25(5):535-42.
10
The Gulf Survey on Anemia Management (GSAM 2005).海湾地区贫血管理调查(2005年海湾地区贫血管理调查)
Saudi J Kidney Dis Transpl. 2007 Jun;18(2):206-14.

引用本文的文献

1
Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: is it feasible?开发促红细胞生成素处方模拟工具以提高促红细胞生成素刺激剂处方能力:是否可行?
BMC Nephrol. 2011 Feb 18;12:11. doi: 10.1186/1471-2369-12-11.